Entering A New Era in MASH: Examining Emerging Disease-Specific Therapies

JOIN US IN-PERSON

JW MARRIOTT WASHINGTON, DC
1331 Pennsylvania Avenue NW | Washington, DC 20004
Capitol Ballroom DEF - Ballroom Level
From the main lobby please take the escaltors or elevators down to the ballroom level

JOIN US LIVESTREAM
To Join via Livestream please click the link below.
https://event.arraylive.com/app/login/8c7b3a66-6168-48b2-8db7-b2964e1df1be

STATEMENT: This program is not affiliated with Digestive Disease Week®.

ACTIVITY OVERVIEW – Metabolic-associated steatotic liver disease (MASLD) is the most frequent cause of chronic liver disease worldwide. Among those with MASLD, nearly one-quarter have metabolic-associated steatohepatitis (MASH). Historically, mitigating disease progression due to MASLD/MASH has been challenging due to a lack of disease-specific therapies. With the approval of the first MASH-specific therapy and several other agents in advanced stages of development comes a new era of disease management. This activity will explore the mechanism of action of thyroid hormone receptor- the evidence on THR-β agonists and other disease-specific therapy classes, considering various study populations, primary and secondary efficacy endpoints, safety, and tolerability (THR- the evidence on THR-β agonists and other disease-specific therapy classes, considering various study populations, primary and secondary efficacy endpoints, safety, and tolerability) agonists and the efficacy of these agents in the treatment of MASH. Recent clinical and safety data of approved and late-stage disease-specific therapies will be examined along with considerations around disease staging to ensure appropriate management. Finally, exploration of case-based scenarios will provide learners with the knowledge of how to individualize the pharmacologic management of patients in this new treatment era.

TARGET AUDIENCE – This initiative is intended for hepatology and gastroenterology healthcare providers, as well as other specialty clinicians involved in the management of patients with MASLD/MASH.

AGENDA

• The Growing Burden of MASLD/MASH: A Call to Action
• THR-β Agonists and Other Disease-Specific Therapies Poised to Change the Paradigm
• Rising to the Need to Improve Diagnosis in the Era of Disease-Specific Therapy
• Clinical Case Challenge: Integrating MASLD/MASH-Specific Therapy Into Practice
• Q&A and Closing Remarks

LEARNING OBJECTIVES
Upon successful completion of this activity, participants should be better able to:

• Describe the mechanistic and clinical rationale for THR-β agonists as a means of treating MASLD/MASH
• Evaluate the evidence on THR-β agonists and other disease-specific therapy classes, considering various study populations, primary and secondary efficacy endpoints, safety, and tolerability
• Review evolving considerations for non-invasive diagnosis/stratification strategies to facilitate access to MASLD/MASH-specific therapy
• Develop appropriate management paradigms for MASLD/MASH that incorporate pharmacotherapy tailored to individual clinical scenarios

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

This activity is supported by an educational grant from Madrigal Pharmaceuticals.

Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Type of Activity: Application-based

Fee Information: There is no fee for this educational activity